DaVita (NYSE:DVA – Get Free Report) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share guidance of $9.00-$9.80 for the period, compared to the consensus earnings per share estimate of $9.30.
DaVita Trading Down 5.5 %
DVA stock traded down $7.79 during trading on Friday, hitting $134.45. The company had a trading volume of 2,541,405 shares, compared to its average volume of 628,593. The firm has a market capitalization of $11.79 billion, a P/E ratio of 15.28, a PEG ratio of 1.20 and a beta of 1.04. DaVita has a 52-week low of $71.51 and a 52-week high of $145.04. The company has a 50 day simple moving average of $133.71 and a 200-day simple moving average of $112.84. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65.
DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping the consensus estimate of $1.95 by $0.43. The company had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 66.59%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.58 EPS. As a group, research analysts forecast that DaVita will post 9.49 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on DaVita
Insider Buying and Selling
In other news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares in the company, valued at $61,629,578.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, COO Michael David Staffieri sold 29,488 shares of DaVita stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total value of $3,532,957.28. Following the sale, the chief operating officer now owns 37,687 shares of the company’s stock, valued at $4,515,279.47. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares in the company, valued at approximately $61,629,578.67. The disclosure for this sale can be found here. Insiders sold a total of 134,540 shares of company stock worth $16,551,071 over the last 90 days. 1.40% of the stock is owned by insiders.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
- Five stocks we like better than DaVita
- How to Calculate Inflation Rate
- MarketBeat Week in Review – 4/29 – 5/3
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- How to invest in marijuana stocks in 7 steps
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.